EUVIMEDEUVIMED entdecken
Crossref

TRIM46 promotes chemoresistance of ovarian cancer via activating PHLPP2/PI3K/AKT pathway

Liang Peng iD, Limei Liu, Ling Xu, Jie Chen, Xiaohui Wang, Meihua Zhang, Yilong Ge

Biochemistry and Cell Biology · 2025

DOI: 10.1139/bcb-2025-0034 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemistry and Cell Biology, 2025. Verfasst von Liang Peng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, The Second People's Hospital of Jingdezhen, Jingdezhen, Jiangxi Province 333000, China. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Proto-Oncogene Proteins c-akt, Phosphatidylinositol 3-Kinases, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Education Department of Jiangxi Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ovarian cancer is one of the most common and lethal malignancy tumors in women. Chemoresistance is one of the main reasons for ovarian cancer relapsing. Understanding the regulatory mechanisms of chemoresistance generation is critical to develop novel therapeutic strategies. Here, we found that TRIM46 was upregulated in ovarian cancer cells and tissues with chemoresistance and associated with poor outcomes. Functional assays showed that TRIM46 promoted cisplatin (CDDP) chemoresistance. Furthermore, TRIM46 interacts with PI3K/AKT pathway inactivator pleckstrin homology domain leucine-rich repeat protein phosphatase 2 (PHLPP2) and downregulated PHLPP2 level. Treating with PI3K/AKT pathway inhibitor significantly reversed the effects of TRIM46-overexpressing on chemoresistance. In summary, our study reveals that TRIM46 promoted chemoresistance via downregulating PHLPP2, leading to activating PI3K/AKT pathway. This study provides a novel potential target for ovarian cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesDrug Resistance, NeoplasmPhosphoprotein PhosphatasesSignal TransductionTripartite Motif ProteinsFemaleHumansCisplatinCell Line, TumorAntineoplastic Agents

Stichwörter der Autor:innen

PHLPP2TRIM46chemoresistanceovarian cancer

Substanzen

Proto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesPhosphoprotein PhosphatasesPHLPP2 protein, humanCisplatinTripartite Motif ProteinsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Gynecology, The Second People's Hospital of Jingdezhen, Jingdezhen, Jiangxi Province 333000, China.
  • Department of General Surgery, Hui Ya Hospital of The First Affiliated Hospital of Sun Yat-sen University, Huizhou, Guangdong, 516081, China.
  • Department of Gynecology and Obstetrics, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi Province 341000, China.
  • Department of Neurology, Hui Ya Hospital of The First Affiliated Hospital of Sun Yat-sen University, Huizhou, Guangdong, 516081, China.
  • Department of Ultrasound medicine, the First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi Province 341000, China.

ORCID-Profile: Liang Peng

Förderung

  • Education Department of Jiangxi Province

Zitieren

APA

Peng, L., Liu, L., Xu, L., Chen, J., Wang, X., Zhang, M., & Ge, Y. (2025). TRIM46 promotes chemoresistance of ovarian cancer via activating PHLPP2/PI3K/AKT pathway. Biochemistry and Cell Biology. https://doi.org/10.1139/bcb-2025-0034

Vancouver

Peng L, Liu L, Xu L, Chen J, Wang X, Zhang M, et al. TRIM46 promotes chemoresistance of ovarian cancer via activating PHLPP2/PI3K/AKT pathway. Biochemistry and Cell Biology. 2025. doi:10.1139/bcb-2025-0034

BibTeX
@article{Peng2025,
  author = {Peng, Liang and Liu, Limei and Xu, Ling and Chen, Jie and Wang, Xiaohui and Zhang, Meihua and Ge, Yilong},
  title = {TRIM46 promotes chemoresistance of ovarian cancer via activating PHLPP2/PI3K/AKT pathway},
  journal = {Biochemistry and Cell Biology},
  year = {2025},
  doi = {10.1139/bcb-2025-0034}
}
Kostenlos starten →